Navigation Links
Despite Dramatic Changes, the Crohn's Disease Drug Market Will Experience Only Moderate Growth Through 2019
Date:9/29/2010

BURLINGTON, Mass., Sept. 29 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues finds that the Crohn's disease drug market will experience moderate growth over the next decade, increasing from $3.2 billion in 2009 to $4.2 billion in 2019 in the United States, France, Germany, Italy, Spain, United Kingdom and Japan. This modest growth rate masks dramatic changes as market growth from newer and emerging biologic agents will outpace the decline in sales of older, established agents, which face increasing generics competition and declining use.

The Pharmacor 2010 findings from the topic entitled Crohn's Disease reveal that sales of biologic agents to treat the disease are concentrated as tumor necrosis factor-alpha (TNF-alpha) inhibitors -- namely Centocor Ortho Biotech/Merck/Mitsubishi Tanabe's Remicade and Abbott/Eisai's Humira -- dominated the Crohn's disease market in 2009, capturing just over three-quarters of major-market sales. Owing to increasing physician familiarity with these agents and continuing emergence of favorable postmarketing clinical trial data, sales of TNF-alpha inhibitors will continue to grow, reaching approximately $2.8 billion in 2019.

The Pharmacor 2010 findings also reveal that the 2008 U.S. launches of Biogen Idec/Elan's Tysabri (a cell adhesion molecule inhibitor) and UCB/Otsuka's TNF-alpha inhibitor Cimzia had a negligible impact on the Crohn's disease market. Through 2019, both agents will continue to be relegated to second- or later-line biological therapy, behind Remicade and Humira.

"In 2009, sales of maintenance therapies for Crohn's disease greatly exceeded sales of acute therapies," said Decision Resources Analyst Kathryn Benton. "We expect growth in the market will be largely attributable to increasing sales of maintenance therapies and that sales of acute therapies will remain essentially flat through 2019. However, no c
'/>"/>

SOURCE Decision Resources
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Study of Brands Shows Tylenol Maintains Consumer Loyalty Despite Recent Quality Challenges
2. Despite Economic Turmoil, CIS Named to Inc. 5000 List of Fastest-Growing Private Companies in America
3. Medical Affairs Budget & Staffing Remain Top Challenges Despite Increased Funding
4. UBM Japan Pharma Events Grow Despite Air Travel Disruptions
5. Medco Study: Despite FDA Warnings, Nearly One-Third of Asthma Patients Still Treated with Long-Acting Beta Agonists Without Controller Medications, Increasing Their Risk for Complications and Hospitalizations
6. R&D Investment by U.S. Biopharmaceutical Companies Remains Strong Despite Ongoing Economic Challenges
7. Despite Limited Capital Equipment Purchases In 2009, The Global Powered Surgical Instrument Market Held Its Value At $800 Million
8. Despite Managed Care Obstacles, Interest and Anticipated Use of Centocor Ortho-Biotechs New Psoriasis Agent Stelara (ustekinumab) is High
9. Central and Eastern European Healthcare Markets Hold Strong Potential for Growth Despite the Economic Slowdown, Says Frost & Sullivan
10. Lifesciences IT Spending to Experience Mature Growth Rates Despite Economic Slowdown, Declares Frost & Sullivan
11. $500 Billion Health Care Spend Boosts BRIC Countries Diagnostic Imaging Sales Despite Global Recession, According to Millennium Research Group
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/3/2015)... June 3, 2015 According ... & Peripheral Vascular Devices Market (Embolic Protection, Chronic ... Stent Grafts, IVC Filters, Stents, Balloons and Accessories) ... Interventional Cardiology and Peripheral Vascular Devices Market is ... with a CAGR of 7.4% from 2014 to ...
(Date:6/3/2015)... Pa. , June 3, 2015  Essential Medical, ... that it has been invited to speak at the ... York city on June 4th.  ... Bore closure system, including a review of first in ...    MANTA closes femoral arterial punctures made ...
(Date:6/3/2015)... MARLBOROUGH, Mass. , June 3, 2015 ... RXII ), a biotechnology company focused on ... the areas of dermatology and ophthalmology, today announced ... from the United States Patent and Trademark ... platform (sd‑rxRNA®). The patent, titled "RNA Interference ...
Breaking Medicine Technology:The Interventional Cardiology and Peripheral Vascular Devices Market Worth $26.72 Billion by 2019 2The Interventional Cardiology and Peripheral Vascular Devices Market Worth $26.72 Billion by 2019 3The Interventional Cardiology and Peripheral Vascular Devices Market Worth $26.72 Billion by 2019 4Essential Medical Inc. Announces Participation in 2015 Jefferies Global Healthcare Conference - NYC 2RXi Pharmaceuticals Granted Notice of Allowance for Patent Covering Lead Compound, RXI-109, for Use in the Eye 2RXi Pharmaceuticals Granted Notice of Allowance for Patent Covering Lead Compound, RXI-109, for Use in the Eye 3RXi Pharmaceuticals Granted Notice of Allowance for Patent Covering Lead Compound, RXI-109, for Use in the Eye 4
... To thank customers for their continuous support of our ... beat watches, blood pressure monitors and so on, Shenzhen ... these products with discounts ranging from 65-20%. ... more suitable products to customers, Wuzhou Changlian has introduced ...
... June 8, 2011 Regulus Therapeutics Inc ., ... innovative medicines targeting microRNAs, and Alnylam Pharmaceuticals, Inc. (Nasdaq: ... today announced the publication in Nature ... antagonism of microRNA-103 and microRNA-107 (miR-103/107). Data from a ...
Cached Medicine Technology:Nature Article Implicates microRNAs in the Pathogenesis of Obesity and Type 2 Diabetes 2Nature Article Implicates microRNAs in the Pathogenesis of Obesity and Type 2 Diabetes 3Nature Article Implicates microRNAs in the Pathogenesis of Obesity and Type 2 Diabetes 4Nature Article Implicates microRNAs in the Pathogenesis of Obesity and Type 2 Diabetes 5Nature Article Implicates microRNAs in the Pathogenesis of Obesity and Type 2 Diabetes 6Nature Article Implicates microRNAs in the Pathogenesis of Obesity and Type 2 Diabetes 7
(Date:6/3/2015)... June 03, 2015 Vancouver personal injury ... the firm will now handle personal injury claims resulting ... on the rise, more and more people turn towards ... accidents cause needless suffering, serious injury and also deaths. ... of a bus accident in BC you may have ...
(Date:6/3/2015)... 03, 2015 VeoMed and Decker ... online and mobile access to premier Continuing Medical ... of Certification (MOC) activities. , ... courses to Decker’s extensive lists of physicians, residents, ... access to VeoMed’s premier online and live-streamed courses. ...
(Date:6/3/2015)... Visual BI Solutions, a leader in ... launch of the second release of its successful ... Studio. The Design Studio EXtension suite allows customers ... into their dashboarding projects. , With the second ... adding key components for customers that are looking ...
(Date:6/3/2015)... Nashville, TN (PRWEB) June 03, 2015 ... Inquisitr police officers intercepted fake oxycodone pills ... fake pills were doctored to look legitimate, and even ... Police officers are warning those consuming 30 mg oxycodone ... order the pills online or buy them illegally on ...
(Date:6/3/2015)... These are challenging and unpredictable times ... number of digital-first business are rewriting the rules for ... serious need for traditional businesses to take on a ... deliver their services. On top of this there ... technology start-ups, to bring new innovation and approaches to ...
Breaking Medicine News(10 mins):Health News:Jiwa Law Corporation Now Handles Personal Injury Claims Involving Bus Accidents 2Health News:VeoMed and Decker Intellectual Properties, the Owner of Scientific American Medicine, Announce a Partnership to Expand Access to Premier Online CME Courses 2Health News:Visual BI Launches Second Release for its Design Studio EXtensions (DSX) for SAP® BusinessObjects™ Design Studio 2Health News:Visual BI Launches Second Release for its Design Studio EXtensions (DSX) for SAP® BusinessObjects™ Design Studio 3Health News:Fake Oxycodone Pills of Fentanyl Discovered in Tennessee by Police 2Health News:Fake Oxycodone Pills of Fentanyl Discovered in Tennessee by Police 3Health News:Chief Digital Officer of Travelex joins Bayer, Abellio and Just Eat at The Open Mobile Summit London 2
... Las Vegas., LAS VEGAS, May 1 YoNaturals ... is launching its healthy vending,program in Las Vegas and ... College Preparatory School and the Las Vegas Convention,Center., ... as other busy locations,in Las Vegas for our YoNaturals ...
... THURSDAY, May 1 (HealthDay News) -- Not having money hurts. ... those making more money, according to a study that had ... their feelings of pain on a scale of 0 to ... incomes below $30,000 a year reported moderate to severe pain ...
... Angeles, London, New Delhi, and Singapore (May 2, 2008) ... the Journal of School Nursing (JOSN) and the NASN ... beginning in August 2008., JOSN provides a forum for ... growth of school nurses, and improving the health of ...
... Growth in Clinical ... Market, SUNNYVALE, Calif., ... the first quarter,of fiscal 2008, an increase of 76 percent over the first ... share, on a,GAAP basis; first quarter net income was $1.7 million, or $0.03 ...
... of Pediatric Cancer and Blood,Disorders, Made Possible ... Foundation, NEW YORK, May 1 A ... Montefiore (CHAM) provides a unique,therapeutic environment for children ... clinical care with comforting,child-friendly design., (Photo: ...
... provided timely intervention , , THURSDAY, May 1 (HealthDay ... of mobile heart failure patients and may reduce ... included 150 patients admitted to Massachusetts General Hospital ... were randomly selected to receive usual care for ...
Cached Medicine News:Health News:Andre Agassi College Preparatory School Welcomes YoNaturals Healthy Vending Program 2Health News:Less Money Means More Hurting 2Health News:Less Money Means More Hurting 3Health News:The National Association of School Nurses selects SAGE to publish its journal 2Health News:Cepheid Reports Record Revenue of $44.8 Million 2Health News:Cepheid Reports Record Revenue of $44.8 Million 3Health News:Cepheid Reports Record Revenue of $44.8 Million 4Health News:Cepheid Reports Record Revenue of $44.8 Million 5Health News:Cepheid Reports Record Revenue of $44.8 Million 6Health News:Cepheid Reports Record Revenue of $44.8 Million 7Health News:Cepheid Reports Record Revenue of $44.8 Million 8Health News:Cepheid Reports Record Revenue of $44.8 Million 9Health News:Cepheid Reports Record Revenue of $44.8 Million 10Health News:New Infusion Suite at the Children's Hospital at Montefiore Blends Child-Friendly Design With Expert Clinical Care 2Health News:New Infusion Suite at the Children's Hospital at Montefiore Blends Child-Friendly Design With Expert Clinical Care 3Health News:New Infusion Suite at the Children's Hospital at Montefiore Blends Child-Friendly Design With Expert Clinical Care 4Health News:Home Monitoring Program Improves Outcomes for Heart Patients 2
... Medicons osteosynthesis systems for maxillo-facial and ... range of screws and plates for the ... adjusting plates and screws ensure that the ... time. The implants are made from titanium. ...
... Timesh 1.6 Titanium Cranial Fixation Systems ... benefits specifically requested by surgeons and ... cranioplasty implants may be either shaped ... procedure warrants, a pre-measured, cut, bent ...
1.0 mm Micro System. The Titanium Micro System is also useful in the practice of ENT, Neurosurgery and Handsurgery....
... Grafton DBM Matrix PLF ... graft material designed specifically ... Unique trough-like design allows ... allograft/autograft bone. Demineralized bone ...
Medicine Products: